Morgan Stanley lowers Biogen price target to $222
Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating on Biogen (NASDAQ: BIIB) while lowering the price target to $222 from $224, signaling a more cautious outlook on the stock's valuation.
*this image is generated using AI for illustrative purposes only.
Morgan Stanley analyst Matthew Harrison has maintained an Equal-Weight rating on Biogen (NASDAQ: BIIB) and lowered the price target to $222 from $224. This adjustment reflects a revised outlook on the company's valuation and market position.
Rating and Target Details
The firm's decision to decrease the price target suggests a more cautious stance on Biogen's near-term performance. The previous target of $224 has been adjusted downward to $222.
| Metric | Value |
|---|---|
| Rating | Equal-Weight |
| Previous Price Target | $224 |
| New Price Target | $222 |
Analyst Perspective
Matthew Harrison of Morgan Stanley continues to hold a neutral view on the stock, maintaining the Equal-Weight status. The revised price target indicates that the analyst sees limited upside potential for Biogen in the current market environment.
What specific market factors are driving the cautious near-term outlook for Biogen?
How might Biogen's upcoming product pipeline influence future analyst ratings?
What impact could competitor performance have on Biogen's market position?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
